CSIMarket Company Name, Ticker, Suppliers, else..
 
Shuttle Pharmaceuticals Holdings Inc   (NASDAQ: SHPH)
 
Price: $3.4600 $-0.07 -1.983%
Day's High: $3.549999952316284 Week Perf: -1.14 %
Day's Low: $ 3.46 30 Day Perf: -18.2 %
Volume (M): 7,775 52 Wk High: $ 55.90
Volume (M$): $ 0 52 Wk Avg: $14.15
Open: $3.55 52 Wk Low: $2.58



 Market Capitalization (Millions $) 17
 Shares Outstanding (Millions) 5
 Employees 2
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -11
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 3

Business Description


Shuttle Pharmaceuticals Holdings Inc is a pharmaceutical company that specializes in the research, development, manufacturing, and distribution of drugs and medical products. The company focuses on developing innovative solutions to address various healthcare challenges. They have a diverse portfolio of products targeting different therapeutic areas, including cardiovascular health, respiratory disorders, infectious diseases, and more. Shuttle Pharmaceuticals aims to improve the quality of life for patients and provide effective treatments for various medical conditions. They also collaborate with other healthcare organizations and invest in research and development to bring new and advanced medications to the market.


   Company Address: 401 Professional Drive Gaithersburg 20879 MD
   Company Phone Number: 403-4212   Stock Exchange / Ticker: NASDAQ SHPH


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADCT   -20.08%    
MDGL   -1.27%    
NRIX        1.88% 
RYTM   -0.79%    
SUPN   -4.5%    
ZYME   -12.04%    
• View Complete Report
   



Clinical Study

Shuttle Pharmaceuticals Advances in Phase 2 Glioblastoma Trial with Ropidoxuridine, Nears 50% Enrollment,

Published Sun, May 11 2025 6:49 PM UTC

Shuttle Pharmaceuticals Approaches Milestone in Phase 2 Clinical Trial for Ropidoxuridine in Glioblastoma Treatment Shuttle Pharmaceuticals Holdings, Inc. a pioneering player in the specialty pharmaceutical sector, has announced significant progress in its Phase 2 clinical trial for Ropidoxuridine, a promising treatment option for glioblastoma, a highly aggressive form of b...
Clinical Study

Progress in Oncology Shuttle Pharma Achieves Key Milestone in Phase 2 Clinical Trial of Ropidoxuridine for Glioblastoma

Published Tue, Jan 21 2025 7:57 PM UTC

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a company dedicated to enhancing the care and outcomes of cancer patients undergoing radiation therapy, has announced a significant milestone in the development of its investigational drug, Ropidoxuridine. As of January 21, 2025, the company reported that it reached a 25% enrollment threshold in the initial randomized ...
Contract

Hope and Hurdles Shuttle Pharmaceuticals Partners with UCSF Amidst Stock Challenges,

Published Thu, Dec 19 2024 2:00 PM UTC

Shuttle Pharmaceuticals: A New Alliance in Cancer Research Amidst Market Challenges In a significant development for both Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) and the broader field of oncology, the company recently announced a sponsored research agreement with the University of California, San Francisco (UCSF) to advance its prostate-specific membrane antige...
Clinical Study

Expansion of Ropidoxuridine Phase 2 Clinical Trial A Promising Step Toward Enhanced Glioblastoma Treatment

Published Tue, Nov 26 2024 2:00 PM UTC

: Shuttle Pharmaceuticals Holdings, Inc. has announced the expansion of its Phase 2 clinical trial evaluating the efficacy of Ropidoxuridine for patients with glioblastoma. With patient enrollment now active at the UVA Cancer Center, this initiative marks a significant stride in the quest for improved radiation therapy outcomes. The study, conducted across six prominent canc...
Management Announcement

Shuttle Pharmaceuticals Reports Financial Struggles Amid Focus on Cancer Treatments

Published Wed, Nov 13 2024 10:00 PM UTC

In a recent corporate update, Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) revealed a challenging financial landscape as it navigates the complexities of the oncology market. The Gaithersburg, Maryland-based company, known for its commitment to enhancing outcomes for cancer patients undergoing radiation therapy, reported a notable decline in its stock value and sign...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 5.2
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.13
Working Capital Ratio 0.3
Leverage Ratio (MRQ) 2.53
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -6.37 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0.22 $
Book Value 0.67 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -5,410,567
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.